Rate of Conversion from Prodromal Alzheimer's Disease to Alzheimer's Dementia: A Systematic Review of the Literature
Open accessThe DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
Background: The purpose of this study was to summarize published estimates for conversion from mild cognitive impairment or amnestic mild cognitive impairment to Alzheimer's dementia. We carried out a systematic review of English language publications to identify cohort studies published since January 2006 that reported the risk or rate of conversion. Summary: Thirty-two cohort studies were identified, of which 14 reported annualized conversion rates (ACRs). Conversions over 1 year ranged from 10.2 to 33.6% (5 studies, median: 19.0%), and over 2 years from 9.8 to 36.3% (7 studies, median: 18.6%). ACRs ranged from 7.5 to 16.5% (7 studies, median: 11.0%) per person-year for studies recruiting from clinics, and from 5.4 to 11.5% (7 studies, median: 7.1%) for community samples. Key Message: Extensive variation was observed in conversion rates due to the population sampled, diagnostic criteria, and duration, and because many studies did not account for loss to follow-up.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“About one-third develop dementia due to Alzheimer's within five years.52”
From 2023 Alzheimer's disease facts and figures (2023) · cites this paper as [52]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“About one‐third develop dementia due to Alzheimer's within five years.”
From 2024 Alzheimer's disease facts and figures (2024) · cites this paper as [52]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & the PRISMA Group* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00135 · Cited by 37,554
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.005 · Cited by 19,575
Mild Cognitive Impairment: Clinical Characterization and Outcome
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980
Mild cognitive impairment as a diagnostic entity
Petersen, R. C. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01388.x · Cited by 7,864
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Winblad, B., Palmer, K., Kivipelto, M., Jelic, V., Fratiglioni, L., Wahlund, L. ‐., Nordberg, A., Bäckman, L., Albert, M., Almkvist, O., et al. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01380.x · Cited by 4,946
Current concepts in mild cognitive impairment
Petersen, R. C., Doody, R., Kurz, A., Mohs, R. C., Morris, J. C., Rabins, P. V., Ritchie, K., Rossor, M., Thal, L., & Winblad, B. (2001) · Archives of Neurology · doi:10.1001/archneur.58.12.1985 · Cited by 4,781
Forecasting the global burden of Alzheimer's disease
Brookmeyer, R., Johnson, E., Ziegler‐Graham, K., & Arrighi, H. M. (2007) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2007.04.381 · Cited by 3,370
Self-citation
Cited by
2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
“A recent systematic review of 32 studies found that an average of 32 percent of individuals with MCI developed Alzheimer’s disease in 5 years [25].”
2023 Alzheimer's disease facts and figures
(2023) · Alzheimer's & Dementia · doi:10.1002/alz.13016 · Cited by 3,212
2024 Alzheimer's disease facts and figures
(2024) · Alzheimer's & Dementia · doi:10.1002/alz.13809 · Cited by 2,536
2019 Alzheimer’s disease facts and figures.
Alzheimer's Association (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.01.010 · Cited by 2,461
“A systematic review, in which data from multiple studies are pooled and summarized, found that 32 percent of individuals with MCI developed Alzheimer’s dementia within 5 years’ follow-up [19].”
2020 Alzheimer's disease facts and figures
(2020) · Alzheimer's & Dementia · doi:10.1002/alz.12068 · Cited by 2,353
2022 Alzheimer's disease facts and figures
(2022) · Alzheimer's & Dementia · doi:10.1002/alz.12638 · Cited by 2,341
2021 Alzheimer's disease facts and figures
(2021) · Alzheimer's & Dementia · doi:10.1002/alz.12328 · Cited by 2,201
2018 Alzheimer's disease facts and figures
Alzheimer's Association (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.001 · Cited by 1,912
2017 Alzheimer's disease facts and figures
(2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.02.001 · Cited by 1,311
“A systematic review of 32 studies found that an average of 32 percent of individuals with MCI developed Alzheimer’s dementia in 5 years [19].”
Timely Diagnosis for Alzheimer’s Disease: A Literature Review on Benefits and Challenges
Dubois, B., Padovani, A., Scheltens, P., Rossi, A., & Dell’Agnello, G. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-150692 · Cited by 562
“For healthcare providers, other possible drawbacks of diagnosis at the pre-dementia stage are an increased risk of misdiagnosis [36] and uncertainty about the rate of progression to dementia, which can vary considerably among individuals [82].”
BackgroundPower, M. C., Adar, S. D., Yanosky, J. D., & Weuve, J. (2016) · NeuroToxicology · doi:10.1016/j.neuro.2016.06.004 · Cited by 422
Economic burden of Alzheimer disease and managed care considerations
(2020) · The American Journal of Managed Care · doi:10.37765/ajmc.2020.88482 · Cited by 398
US Preventive Services Task Force, Owens, D. K., Davidson, K. W., Krist, A. H., Barry, M. J., Cabana, M., Caughey, A. B., Doubeni, C. A., Epling, J. W., Kubik, M., et al. (2020) · JAMA · doi:10.1001/jama.2020.0435 · Cited by 374
Liss, J. L., Seleri Assunção, S., Cummings, J., Atri, A., Geldmacher, D. S., Candela, S. F., Devanand, D. P., Fillit, H. M., Susman, J., Mintzer, J., et al. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13244 · Cited by 312
Recent Progresses in Machine Learning Assisted Raman Spectroscopy
Qi, Y., Hu, D., Jiang, Y., Wu, Z., Zheng, M., Chen, E. X., Liang, Y., Sadi, M. A., Zhang, K., & Chen, Y. P. (2023) · Advanced Optical Materials · doi:10.1002/adom.202203104 · Cited by 250
The impact of diabetes on cognitive impairment and its progression to dementia
Dove, A., Shang, Y., Xu, W., Grande, G., Laukka, E. J., Fratiglioni, L., & Marseglia, A. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12482 · Cited by 252
Ravanfar, P., Loi, S. M., Syeda, W. T., Van Rheenen, T. E., Bush, A. I., Desmond, P., Cropley, V. L., Lane, D. J. R., Opazo, C. M., Moffat, B. A., et al. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.618435 · Cited by 229
Yoon, S. P., Grewal, D. S., Thompson, A. C., Polascik, B. W., Dunn, C., Burke, J. R., & Fekrat, S. (2019) · Ophthalmology Retina · doi:10.1016/j.oret.2019.02.002 · Cited by 228
Eye Movements in Alzheimer's Disease
Molitor, R. J., Ko, P. C., & Ally, B. A. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-141173 · Cited by 216
Current treatment options for Alzheimer’s disease and Parkinson’s disease dementia
Y.Y. Szeto, J., & J.G. Lewis, S. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666151208112754 · Cited by 198
“The annual rate of transition from MCI to AD is estimated as 19% [2] and as such the early identification of this prodromal stage might afford critical opportunities for intervention.”
BackgroundCheng, Y.-W., Chen, T.-F., & Chiu, M.-J. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s123428 · Cited by 150
“5% for community samples.(15) Consistent with previous findings that identified memory decline as the initial symptom of AD, amnestic MCI was associated with a higher risk of progression to AD in several longitudinal studies.”
Clinical practice guidelines for dementia in Australia
Laver, K., Cumming, R. G., Dyer, S. M., Agar, M. R., Anstey, K. J., Beattie, E., Brodaty, H., Broe, T., Clemson, L., Crotty, M., et al. (2016) · Medical Journal of Australia · doi:10.5694/mja15.01339 · Cited by 134
Ryzhikova, E., Ralbovsky, N. M., Sikirzhytski, V., Kazakov, O., Halámková, L., Quinn, J. F., Zimmerman, E. A., & Lednev, I. K. (2020) · Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy · doi:10.1016/j.saa.2020.119188 · Cited by 146
Neurons, Nose, and Neurodegenerative Diseases: Olfactory Function and Cognitive Impairment
Fatuzzo, I., Niccolini, G. F., Zoccali, F., Cavalcanti, L., Bellizzi, M. G., Riccardi, G., VINCENTIIS, M. D., Fiore, M., Petrella, C., Minni, A., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032117 · Cited by 140
“In addition to UPSIT scores, measures of episodic verbal memory, informant reports of functional decline, and magnetic resonance imaging of hippocampal and entorhinal cortex atrophy had a strong value (90% specificity and 85% sensitivity) to predict accuracy for the transition from MCI to AD varying across studies [97…”
Progression of mild cognitive impairment to dementia due to AD in clinical settings
Tifratene, K., Robert, P., Metelkina, A., Pradier, C., & Dartigues, J. F. (2015) · Neurology · doi:10.1212/wnl.0000000000001788 · Cited by 124
“strict MCI inclusion criteria used in those studies.(6,13,14) The prognosis for MCI varies according to the MCI subtype with aMCI having higher risk for progression to dementia due to AD than naMCI.”
BackgroundMethodWilcockson, T. D. W., Mardanbegi, D., Xia, B., Taylor, S., Sawyer, P., Gellersen, H. W., Leroi, I., Killick, R., & Crawford, T. J. (2019) · Aging · doi:10.18632/aging.102118 · Cited by 118
“Critically, there is a higher conversation rate to dementia due to AD for people diagnosed with aMCI, than naMCI [15-17].”
BackgroundGómez‐Ramírez, J., Ávila‐Villanueva, M., & Fernández‐Blázquez, M. A. (2020) · Scientific Reports · doi:10.1038/s41598-020-77296-4 · Cited by 127
Li, Y., Liu, J., Gao, X., Jie, B., Kim, M., Yap, P., Wee, C.-Y., & Shen, D. G. (2018) · Medical Image Analysis · doi:10.1016/j.media.2018.11.006 · Cited by 114
Zimmermann, J., Perry, A., Breakspear, M. J., Schirner, M., Sachdev, P. S., Wen, W., Kochan, N. A., Mapstone, M., Ritter, P., McIntosh, A. R., et al. (2018) · NeuroImage Clinical · doi:10.1016/j.nicl.2018.04.017 · Cited by 110
Jones, A., Ali, M. U., Kenny, M., Mayhew, A., Mokashi, V., He, H. T., Lin, S. H., Yavari, E., Paik, K., Subramanian, D., et al. (2024) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000536643 · Cited by 128
McGrattan, A., Pakpahan, E., Siervo, M., Mohan, D., Reidpath, D. D., Prina, M. A., Allotey, P. A., Zhu, Y., Shulin, C., Yates, J., et al. (2022) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12267 · Cited by 111
Wallensten, J., Ljunggren, G., Nager, A., Wachtler, C., Bogdanović, N., Petrović, P., & Carlsson, A. C. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01308-4 · Cited by 123
Wolk, D. A., Sadowsky, C., Safirstein, B., Rinne, J. O., Duara, R., Perry, R., Agronin, M., Gamez, J., Shi, J., Ivanoiu, A., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.0894 · Cited by 87
Su, Y., Dong, J., Sun, J., Zhang, Y., Ma, S., Li, M., Zhang, A., Cheng, B., Cai, S., Bao, Q., et al. (2021) · BMC Geriatrics · doi:10.1186/s12877-021-02471-9 · Cited by 95
RetractedChen, J. J., Thiyagarajah, M. T., Song, J., Chen, C. C., Herrmann, N., Gallagher, D., Rapoport, M. J., Black, S. E., Ramirez, J., Andreazza, A. C., et al. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-00961-5 · Cited by 99
“Those with MCI have greater risk of conversion to AD than the normal population, with conversion rates ranging from 10 to 36% over a 2-year period depending on the methods used and the population under study [5].”
MethodSyaifullah, A. H., Shiino, A., Kitahara, H., Ito, R., Ishida, M., & Tanigaki, K. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2020.576029 · Cited by 87
“However, it has become apparent that only 50% convert to AD even in a long-term follow-up period (16).”
BackgroundEye-tracking paradigms for the assessment of mild cognitive impairment: a systematic review
Wolf, A., Tripanpitak, K., Umeda, S., & Otake, M. (2023) · Frontiers in Psychology · doi:10.3389/fpsyg.2023.1197567 · Cited by 98
“, 2015), amnestic and multiple-domain MCI subtypes have been proposed to pose an equal risk for Alzheimer’s disease (AD) progression (Petersen et al., 1999; Gauthier et al., 2006; Fischer et al., 2007; Ward et al., 2013; Ataollahi Eshkoor et al., 2015; Dunne et al., 2021).”
BackgroundCognitive Function in a Sleep Clinic Cohort of Patients with Obstructive Sleep Apnea
Beaudin, A. E., Raneri, J. K., Ayas, N., Skomro, R. P., Fox, N., Allen, A. J. M. H., Bowen, M. W., Nocon, A., Lynch, E. J., Wang, M., et al. (2020) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202004-313oc · Cited by 81
Gomes-Osman, J., Indahlastari, A., Fried, P. J., Cabral, D. L. F., Rice, J., Nissim, N. R., Aksu, S., McLaren, M. E., & Woods, A. J. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00177 · Cited by 77
“In addition, more than 30% of individuals with MCI will develop Alzheimer’s disease (AD) (Ward et al., 2013) or other types of dementia (Mitchell and Shiri-Feshki, 2009) within 5 years.”
Background(2020) · doi:10.1016/j.neurobiolaging.2020.12.005 · Cited by 78
“In conclusion, the current clinical evaluation protocols cannot accurately predict which patients with MCI will progress to DAT (Ward et al., 2013).”
Amyloid‐β PET in Alzheimer's disease: A systematic review and Bayesian meta‐analysis
Ruan, D., & Sun, L. (2023) · Brain and Behavior · doi:10.1002/brb3.2850 · Cited by 74
“It has been shown that approximately 6%–16.5% ofMCI patients convert to AD each year (Bruscoli & Lovestone, 2004; Ward et al., 2013).”
BackgroundInfluentialDing, D., Zhao, Q., Guo, Q., Liang, X., Luo, J., Yu, L., Zheng, L., Hong, Z., & (SAS), S. A. S. (2016) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2016.03.004 · Cited by 85
“Prospective studies are needed to further examine risk and protective predictors and to seek proper interventions for cognitive decline.”
Current and evolving treatment strategies for the Alzheimer disease continuum
(2020) · The American Journal of Managed Care · doi:10.37765/ajmc.2020.88481 · Cited by 66
Strand, B. H., Knapskog, A.-B., Persson, K., Edwin, T. H., Amland, R., Mjørud, M., Bjertness, E., Engedal, K., & Selbæk, G. (2018) · PLOS ONE · doi:10.1371/journal.pone.0204436 · Cited by 64
Vaughan, R. M., Coen, R. F., Kenny, R. A., & LAWLOR, B. A. (2018) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15294 · Cited by 76
“5% in community-based samples.(1) Several available screening measures afford the ability to detect MCI, but in a systematic review of those measures, none was satisfactory in accurately predicting the course and progression of the condition.”
BackgroundBody Mass Index Trajectories Preceding Incident Mild Cognitive Impairment and Dementia
Guo, J., Wang, J., Dove, A., Chen, H., Yuan, C., Bennett, D. A., & Xu, W. (2022) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2022.3446 · Cited by 62
“Over the follow-up period (median [IQR] duration, 6 [3-9] years), 371 participants (39.”
Lee, E., Choi, J.-S., Kim, M., & Suk, H.-I. (2019) · NeuroImage · doi:10.1016/j.neuroimage.2019.116113 · Cited by 61
“This condition, called mild cognitive impairment (MCI), does not always lead to dementia, but an average of 32% percent of individuals with MCI develop AD-related dementia within fi ve years (Ward et al., 2013).”
BackgroundA Single Model Deep Learning Approach for Alzheimer’s Disease Diagnosis
Zhang, F., Pan, B., Shao, P., Liu, P., Shen, S., Yao, P., & Xu, R. X. (2022) · Neuroscience · doi:10.1016/j.neuroscience.2022.03.026 · Cited by 77
“Mild cognitive impairment (MCI) represents a slight decline of mental ability along the continuum from normal cognition to AD, while over 33% of MCI subjects will progress to AD within five or more years (Ward et al., 2013; Livingston et al., 2017).”
Alzheimer’s disease and drug delivery across the blood–brain barrier: approaches and challenges
Iqbal, I., Saqib, F., Mubarak, Z., Latif, M. F., Wahid, M., Nasir, B., Shahzad, H., Sharifi-Rad, J., & Mubarak, M. S. (2024) · European Journal of Medical Research · doi:10.1186/s40001-024-01915-3 · Cited by 60
“Compared to the 1–2% conversion rate of AD in healthy aging, 10 to 15% of people with MCI develop AD each year [8].”
BackgroundSubjective Cognitive Decline Is Associated with Greater White Matter Hyperintensity Volume
van Rooden, S., van den Berg‐Huysmans, A. A., Croll, P. H., Labadie, G., Hayes, J. M., Viviano, R. P., van der Grond, J., Rombouts, S. A. R. B., & Damoiseaux, J. S. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180285 · Cited by 65
“AD is the most common form of dementia, and therefore the most common cause of mild cognitive impairment (MCI) and possibly SCD [16, 17].”
BackgroundYang, T., Liu, W., He, J., Gui, C., Meng, L., Xu, L., & Jia, C. (2024) · Alzheimer's Research & Therapy · doi:10.1186/s13195-024-01505-9 · Cited by 59
“Among those with MCI, about 15% would develop dementia after 2 years, and 33% progress to AD within 5 years [4, 5].”
BackgroundZheng, W., Yao, Z., Xie, Y., Fan, J., & Hu, B. (2018) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2018.06.004 · Cited by 73
Different Patterns of Theory of Mind Impairment in Mild Cognitive Impairment
Moreau, N., Rauzy, S., Bonnefoi, B., Renié, L., Martinez-Almoyna, L., Viallet, F., & Champagne‐Lavau, M. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-143021 · Cited by 63
Hypothesis review: Alzheimer's overture guidelines
Ferrer, I. (2022) · Brain Pathology · doi:10.1111/bpa.13122 · Cited by 57
Katzorke, A., Zeller, J. B. M., Müller, L. D., Lauer, M., Polak, T. T., Deckert, J., & Herrmann, M. J. (2018) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2018.02.003 · Cited by 57
Trace elements and Alzheimer dementia in population-based studies: A bibliometric and meta-analysis
Li, K., Li, A., Mei, Y., Zhao, J., Zhou, Q., Li, Y., Yang, M., & Xu, Q. (2022) · Environmental Pollution · doi:10.1016/j.envpol.2022.120782 · Cited by 56
Precision Aging: Applying Precision Medicine to the Field of Cognitive Aging
Ryan, L., Hay, M., Huentelman, M. J., Duarte, A., Rundek, T., Levin, B. E., Soldan, A., Pettigrew, C. A., Mehl, M. R., & Barnes, C. A. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00128 · Cited by 61
Thaipisuttikul, P., Jaikla, K., Satthong, S., & Wisajun, P. (2022) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12272 · Cited by 69
Marcos, G., Santabárbara, J., López‐Antón, R., De‐la‐Cámara, C., Gracia‐García, P., Lobo, E., Pírez, G., Menchón, J. M., Palomo, T., Stephan, B. C. M., et al. (2015) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12543 · Cited by 66
“Our finding of the continued progression to dementia with the increase in follow-up time contradicts a study that suggests that the CR is particularly high early in the follow-up period (36), but is consistent with the conclusions of a more recent systematic review (7).”
BackgroundResultInfluentialConversion and Reversion Rates in Japanese Older People With Mild Cognitive Impairment
Shimada, H., Makizako, H., Doi, T., Lee, S., & Lee, S. (2017) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2017.05.017 · Cited by 52
A Survey of Deep Learning for Alzheimer’s Disease
Zhou, Q., Wang, J., Yu, X., Wang, S., & Zhang, Y. (2023) · Machine Learning and Knowledge Extraction · doi:10.3390/make5020035 · Cited by 69
“Multiple studies have analyzed the demographics and progression of MCI and have found the following: 15–20% of people age 65 or older have MCI from a range of possible causes [23]; 15% of people age 65 or older with MCI developed dementia at two years follow-up [24]; and 32% developed AD and 38% developed dementia at…”
BackgroundNutrients for neurocognition in health and disease: Measures, methodologies and mechanisms
Scholey, A. (2018) · Proceedings of The Nutrition Society · doi:10.1017/s0029665117004025 · Cited by 49
“general knowledge and some verbal skills, remain relatively unscathed by the ageing process((10,32)).”
BackgroundTao, D., Scully, R., Ash, G. I., Pei, Z., Gu, Y., Gao, Y., Cole, A. M., & Baker, J. S. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102120 · Cited by 64
Petrazzuoli, F., Vestberg, S., Midlöv, P., Thulesius, H., Stomrud, E., & Palmqvist, S. (2020) · Journal of Alzheimer’s Disease · doi:10.3233/jad-191191 · Cited by 49
Kandiah, N., Chan, Y. F., Chen, C., Dasig, D., Dominguez, J. C., Han, S., Jia, J., Kim, S., Limpawattana, P., Ng, L., et al. (2020) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13536 · Cited by 51
Paitel, E. R., Otteman, C., Polking, M. C., Licht, H. J., & Nielson, K. A. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1496235 · Cited by 60
The Vallecas Project: A Cohort to Identify Early Markers and Mechanisms of Alzheimer’s Disease
Olazarán, J., Valentí, M., Frades, B., Zea‐Sevilla, M. A., Ávila‐Villanueva, M., Fernández‐Blázquez, M. A., Calero, M., Dobato, J. L., Hernandez-Tamames, J. A., León‐Salas, B., et al. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00181 · Cited by 51
“Conversion from MCI to dementia has been more widely studied, with a duration of 7–10 years for theMCI stage and annualized conversion rates of 8–17 per 100 person-years (Ward et al., 2013).”
MethodFarina, E., Baglio, F., Pomati, S., D'Amico, A., Campini, I., Tella, S. D., Belloni, G., & Pozzo, T. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00371 · Cited by 48
“…is sometimes difficult to define), MCI is a useful clinical concept because it is a well-recognized risk factor for dementia (Busse et al., 2003; Ward et al., 2013) and therefore, represents a critical window of opportunity to intervene and alter the trajectory of both cognitive and functional…”
BackgroundScreening for Early-Stage Alzheimer’s Disease Using Optimized Feature Sets and Machine Learning
Kleiman, M. J., Barenholtz, E., Galvin, J. E., & Initiative, F. T. A. D. N. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201377 · Cited by 44
“Approximately 32% of patients with MCI go on to develop AD within 5 years [7].”
The Potential of Naturalistic Eye Movement Tasks in the Diagnosis of Alzheimer’s Disease: A Review
Readman, M. R., Polden, M., Gibbs, M. C., Wareing, L., & Crawford, T. J. (2021) · Brain Sciences · doi:10.3390/brainsci11111503 · Cited by 57
Incidence of Mild Cognitive Impairment, Conversion to Probable Dementia, and Mortality
Zhang, Y., Natale, G., & Clouston, S. (2021) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/15333175211012235 · Cited by 58
“However, previous estimates of incidence and conversion rates primarily come from Cox proportional survival models and ratio estimates, which generally concentrate on time to the outcome of one cognitive event at a time but cannot examine the potential for reversion.(6,7) Fragmented estimates can cause loss of informa…”
BackgroundKwak, K., Niethammer, M., Giovanello, K. S., Styner, M. A., Dayan, E., & Initiative, A. D. N. (2021) · Cerebral Cortex · doi:10.1093/cercor/bhab223 · Cited by 46
“Namely, up to 33% of individuals with MCI convert to AD over 5 years (Ward et al. 2013), with annual conversion rates of about 7% (Mitchell and Shiri-Feshki 2009),but others may remain stable or even revert to normal or near-normal cognition levels (Koepsell and Monsell 2012).”
Cirillo, G., Pepe, R., Siciliano, M., Ippolito, D., Ricciardi, D., Stefano, M. D., Buonanno, D., Atripaldi, D., Abbadessa, S., Perfetto, B., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043231 · Cited by 44
“It has been classified as a prodromal stage of a variety of dementing disorders, including Alzheimer’s disease (AD) [2].”
BackgroundSignificance of Subjective Memory Complaints in the Clinical Setting
Silva, D., Guerreiro, M., Faria, C. S., Marôco, J. P., Schmand, B. A., & de Mendonça, A. (2014) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988714532018 · Cited by 45
“%) fits quite well the values previously reported for patients with MCI.47 The clinical significance of subjective memory complaints in the elderly individuals likely depends upon the characteristics of participants and the settings where they are recruited.”
ResultInfluentialDeep learning for the dynamic prediction of multivariate longitudinal and survival data
Lin, J. J., & Luo, S. (2022) · Statistics in Medicine · doi:10.1002/sim.9392 · Cited by 57
“In our analysis, we made predictions at landmark times t = [ 1 , 2 , 3 , 4 , 5 ] .”
MethodQuantitative MRI of Perivascular Spaces at 3T for Early Diagnosis of Mild Cognitive Impairment
Niazi, M. Z., Karaman, M., Das, S. R., Zhou, X. J., Yushkevich, P. A., & Cai, K. (2018) · American Journal of Neuroradiology · doi:10.3174/ajnr.a5734 · Cited by 43
“Anywhere from 32%–38% of individuals with MCI progress to AD in 5 years or longer.(32,33) Annual rates of progression have been estimated to be 10%–15%.”
BackgroundPlachokova, A. S., Gjaltema, J., Hagens, E., Hashemi, Z., Knüppe, T., Kootstra, T. J. M., Visser, A., & Bloem, B. R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084504 · Cited by 46
“Relevant and promising findings from systematic reviews on AD are that 32% of the MCI cases would convert into AD within 5 years [50] and this process seems reversible, overall rate 10% [51].”
BackgroundBermejo‐Pareja, F., Contador, I., Trincado, R., Lora, D., Sánchez‐Ferro, Á., Mitchell, A. J., Boycheva, E., Herrero, A., Hernández‐Gallego, J., Velasco, S. L., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150625 · Cited by 47
Fujishima, M., Kawaguchi, A., Maikusa, N., Kuwano, R., Iwatsubo, T., Matsuda, H., (ADNI), F. T. J. A. D. N. I., & (J-ADNI), T. J. A. D. N. I. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160621 · Cited by 43
“[5], conversion rates from MCI or amnestic MCI to AD dementia over 5 or more years were greater than 33% in most clinic-based and community-based studies [6–9].”
BackgroundLin, J. J., Li, K., & Luo, S. (2020) · Statistical Methods in Medical Research · doi:10.1177/0962280220941532 · Cited by 54
“3,4 As such, it is of interest to build prognostic models that are robust in predicting conversion of MCI to AD prior to complete disease onset, as this would allow physicians to adopt earlier intervention strategies.”
Disease progression modelling from preclinical Alzheimer’s disease (AD) to AD dementia
Cho, S. H., Woo, S., Kim, C., Kim, H. J., Jang, H., Kim, B. C., Kim, S. E., Kim, S. J., Kim, J. P., Jung, Y. H., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-83585-3 · Cited by 38
Hu, X. Y., Zhang, J., Qiu, Y., & Liu, Z. (2021) · Psychogeriatrics · doi:10.1111/psyg.12743 · Cited by 58
Magnetic Resonance Imaging to Detect Early Molecular and Cellular Changes in Alzheimer's Disease
Knight, M. J., McCann, B., Kauppinen, R. A., & Coulthard, E. J. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00139 · Cited by 45
“The annualized conversion rate from MCI to AD is around 10% (Ward et al., 2013), but many patients with symptoms of MCI will not develop dementia (even when there is some biomarker evidence of AD, Jack et al., 2016) and some will develop non-AD dementia.”
BackgroundMichaud, T. L., Siahpush, M., Farazi, P. A., Kim, J., Yu, F., Su, D., & Murman, D. L. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180278 · Cited by 43
Song, D., Yu, D. S. F., Li, P. W. C., He, G., & Sun, Q. (2019) · Clinical Interventions in Aging · doi:10.2147/cia.s227767 · Cited by 38
Costanzo, M., Cutrona, C., Leodori, G., Malimpensa, L., D’Antonio, F., Conte, A., & Belvisi, D. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01607-4 · Cited by 44
“Evidence from cross-sectional and longitudinal studies indicates that MCI patients show an annual conversion rate of 5–17% to AD [12].”
BackgroundChen, T., Lai, Y.-H., Ke, T.-L., Chen, J.-P., Lee, Y.-J., Lin, S.-Y., Lin, P.-C., Wang, P., & Cheng, I. H.-J. (2019) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000505435 · Cited by 40
Olfactory Identification in Subjective Cognitive Decline: A Meta-Analysis
Jobin, B., Zahal, R., Bussières, È.-L., Frasnelli, J., & Boller, B. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201022 · Cited by 44
“Since MCI is considered as an early clinical stage of dementia [5], with a variable annual conversion rate from MCI to AD dementia of 7.5 to 16.5% [16], researchers have investigated the possible role of olfactory dysfunction as a predictor for the conversion from MCI to AD.”
InfluentialLiu, H., Zhang, D., Lin, H., Zhang, Q., Zheng, L., Zheng, Y., Yin, X., Li, Z., Liang, S., & Huang, S. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.738971 · Cited by 41
Polden, M., Wilcockson, T. D. W., & Crawford, T. J. (2020) · Brain Sciences · doi:10.3390/brainsci10070461 · Cited by 40
Hurtado, M. O., Kohler, I., & de Lange, E. C. M. (2018) · Bioanalysis · doi:10.4155/bio-2018-0135 · Cited by 34
Increased Prevalence of Vestibular Loss in Mild Cognitive Impairment and Alzheimer’s Disease
Wei, E. X., Oh, E. S., Harun, A., Ehrenburg, M., Xue, Q., Simonsick, E. M., & Agrawal, Y. (2020) · Current Alzheimer Research · doi:10.2174/1567205016666190816114838 · Cited by 38
Xu, Y., Zhu, J., Liu, H., Qiu, Z., Wu, M., Liu, J., Wu, J., Huang, J., Liu, Z., Liu, W., et al. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1199246 · Cited by 39
The AT(N) framework for Alzheimer's disease in adults with Down syndrome
Rafii, M. S., Ances, B. M., Schupf, N., Krinsky‐McHale, S. J., Mapstone, M., Silverman, W., Lott, I., Klunk, W., Head, E., Christian, B., et al. (2020) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12062 · Cited by 33
Bauer, C. M., Cabral, H., & Killiany, R. (2018) · Diagnostics · doi:10.3390/diagnostics8010014 · Cited by 40
Mar, J., Soto‐Gordoa, M., Arrospide, A., Moreno, F., & Martínez‐Lage, P. (2015) · Alzheimer s Research & Therapy · doi:10.1186/s13195-014-0079-9 · Cited by 35
“This variability derives from the heterogeneity of samples from patients with MCI, which includes both clinical studies (high rates) and population studies (low rates), so we applied a 10% rate that resulted in a duration of 10 years by application of the exponential function [23].”
MethodMyette‐Côté, É., St‐Pierre, V., Beaulieu, S., Castellano, C., Fortier, M., Plourde, M., Bocti, C., Fülöp, T., & Cunnane, S. C. (2020) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2020.102236 · Cited by 39
Olfactory Measures as Predictors of Conversion to Mild Cognitive Impairment and Alzheimer’s Disease
Wheeler, P. L., & Murphy, C. (2021) · Brain Sciences · doi:10.3390/brainsci11111391 · Cited by 34
“However, transition rates have varied across studies [7,8].”
BackgroundIllakiya, T., & Karthik, R. (2023) · IEEE Access · doi:10.1109/access.2023.3332122 · Cited by 34
“Research findings suggest conversion rates from MCI to AD ranging from 10.2% to 33.6% within one year and from 9.8% to 36.3% within two years, highlighting the importance of early detection in achieving more favorable outcomes [2].”
BackgroundInfluentialSong, Y., Yuan, Q., Liu, H., Gu, K., & Liu, Y. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.09.059 · Cited by 36
Metadata
- Authors
- Ward, A., Tardiff, S., Dye, C., & Arrighi, H. M.
- Affiliations
- Janssen Alzheimer Immunotherapy Research & Development (United States) (US)
- Corresponding author
- Arrighi, H. Michael
- ORCID
- Ward, Alex
- Venue
- Dementia and Geriatric Cognitive Disorders Extra
- Publisher
- S. Karger AG
- Published
- 2013-09-28
- Volume
- 3
- Issue
- 1
- Pages
- 320-332
- ISSN
- 1664-5464 (ISSN-L)
- PMC
- PMC3808216
- OpenAlex
- W2010643121
- Cited by
- 426
- References
- 68
- Citations by year
- 2026: 28 · 2025: 47 · 2024: 64 · 2023: 61 · 2022: 44 · 2021: 60 · 2020: 32 · 2019: 30 · 2018: 26 · 2017: 5 · 2016: 14 · 2015: 11 · 2014: 4
- FWCI
- 1.32
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/3.0/ (vor)
- creativecommons.org/licenses/by-nc/3.0/ (tdm)
- Locations
- Dementia and Geriatric Cognitive Disorders Extra (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Keywords
- prodromal Alzheimer's disease, Alzheimer's dementia, conversion rate, mild cognitive impairment, amnestic mild cognitive impairment, cohort studies, loss to follow-up, diagnostic criteria
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
